Prevention of Cancer
Risk Assessment through Precision Screening and Genetic Insights.
Boost survival with early detection. Our MammoReady™ and Hereditary Cancer Tests identify high-risk individuals, enabling proactive, accurate care to reduce cancer risk and take control of your health.
- Improved Survival: Early cancer detection leads to higher survival rates through proactive treatment.
- Personalized Screening: Genetic insights provide targeted screening based on individual risk factors.
Backed by Science, Built for You
Improving screening and early detection in cancer significantly increases survival rate.
| Cancer Stage | % Cases Diagnosed (Average) | 5-Year Survival Rate (%) | ||
|---|---|---|---|---|
| Stage I | 2.42 | 94.3 | ||
| Stage II | 18.21 | 75 | ||
| Stage III | 32.33 | 31 | ||
| Stage IV | 47.71 | 11.7 |
Cancer arises due to genetic mutations, which can be inherited (germline) or acquired (somatic).
Germline sequencing can identify individuals who are at higher risk. Based on the Chinese Health Study, 51% more cancers can be detected if screening was more targeted based on their risk profiles, compared to random screening of 35% of the population.
Who Can Benefit from this?
Although almost all individuals can take the test, our tests are especially helpful for individuals who have primary family history.
Breast cancer risk assessment for early screening (ages 35-49).
Identifies inherited cancer risks for preventive care.
Why Choose Us
We can help you:
MammoReady
High accuracy in breast cancer risk stratification.
Hereditary Cancer Panel
100% sensitivity, 99.9% specificity.
Fast, Secure, & Science-Backed Testing
MammoReady:
- Sample Type Buccal Swab
- Turnaround Time is 2-4 Weeks
- Platform using Microarray and Next-generation Sequencing
- Result availability on Nala Clinical Decision and Nala PHM
- Analysis at Nalagenetics Pte Ltd (Indonesia)
Strand:
- Sample Type Whole Blood
- Tunraround Time is 21 days
- Platform using Next-generation Sequencing
- Result availability on PDF Report via email
- Analysis at Strand Life Science (India)
What Happens After You Get Your Results?
Backed by Science, Trusted by Experts
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancers:
BRCA1/2 dan Gen Lain dengan Penetrasi Tinggi: NCCN merekomendasikan pengujian genetik untuk individu dengan riwayat pribadi atau keluarga yang menunjukkan kemungkinan sindrom kanker payudara, ovarium, atau pankreas herediter. I...
What Report Do I Get?
Strand
With 10% of cancers being hereditary and survival rates dropping from >90% at Stage 1 to <30% at Stage 4, early detection is key. Our genomic test helps identify high-risk individuals for precise treatment and better outcomes.
-
98% sensitivity & specificity
- Covers 30+ hereditary cancer genes by ACMG & NCCN
- Offers ACMG-recommended cancer screening (breast, ovarian, pancreatic, prostate, colorectal, endometrial)
MammoReady™
MammoReady™ helps you understand your breast cancer risk and take proactive steps.
This test provides a genetic report covering three types of risks :
- Polygenic RIsk: Using a model designed for breast cancer, we examine 313 single nucleotide
- Monogenic Risk: Focuses on key genes associated with breast cancer, including BRCA 1, BRCA 2, and PALB2.
- Clinical Risk: Includes family history, lifestyle, and medical history.
Better Health, Backed by Genetics - At the Right Price
Choose the right package for you:
Find the right DNA test for you and your loved ones
Unlock total genetic insights to guide your health, nutrition, and wellness journey with personalized and preventive precision
For Individuals
Find our DNA Test product to align with your Goals
